Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile
Chirosynkem laboratories Pvt Ltd

@chirosynkem

we specialize in the design and synthesis of small molecules, hit to lead optimization, email: [email protected], drugdiscoveryhub.com

ID: 1666422421849800704

linkhttps://chirosynkem.com/ calendar_today07-06-2023 12:31:12

164 Tweet

301 Takipçi

3,3K Takip Edilen

Jonathan George (@jonathanhgeorge) 's Twitter Profile Photo

Latest total synthesis is on ChemRxiv - a truly comprehensive dearomatization strategy! Congratulations to Andreas zur Bonsen and thanks to Chris Sumby for the X-ray structures Bioinspired Total Synthesis of Hyperireflexolides A and B | ChemRxiv - go.shr.lc/3DbWbkc

Latest total synthesis is on ChemRxiv - a truly comprehensive dearomatization strategy!
Congratulations to <a href="/AndreaszBonsen/">Andreas zur Bonsen</a> and thanks to <a href="/chriszombiechem/">Chris Sumby</a> for the X-ray structures

Bioinspired Total Synthesis of Hyperireflexolides A and B | ChemRxiv - go.shr.lc/3DbWbkc
Scott Bagley (@bagphos) 's Twitter Profile Photo

Huge thanks to CSU Department of Chemistry for hosting #PfizerChemistry for a virtual outreach today and Andy McNally and Bandar Labs and everyone else for joining in (and listening to me go on for too long talking about GLP-1 agonists) doi.org/10.1021/acs.jm…

Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

CNS drug: Ozanimod: In 2020, the FDA authorised ozanimod for the treatment of relapse multiple sclerosis, which includes active secondary progressive multiple sclerosis , clinically isolated syndrome, and relapsing-remitting multiple sclerosis.  drugdiscoveryhub.com/central-nervou…

Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

New class of oral small molecule drug: Ritlecitinib. Ritlecitinib is used for treating severe alopecia areata, which causes hair loss on the scalp and other parts of the body. Litfulo was approved by the FDA in June 2023. drugdiscoveryhub.com/new-class-of-o…

Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

The Latest Advancements in Small Molecule Drugs for Insomnia.#insomnia #Daridorexant #Lemborexant My Blog: drugdiscoveryhub.com/the-latest-adv…

The Latest Advancements in Small Molecule Drugs for Insomnia.#insomnia #Daridorexant #Lemborexant
My Blog: drugdiscoveryhub.com/the-latest-adv…
Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

Treatment of sickle cell disease (SCD): Osivelotor (GBT-601), a second-generation drug. #sicklecelldisease #Osivelotor #GBT601 My blog: drugdiscoveryhub.com/treatment-of-s…

Treatment of sickle cell disease (SCD): Osivelotor (GBT-601), a second-generation drug. #sicklecelldisease #Osivelotor #GBT601
My blog: drugdiscoveryhub.com/treatment-of-s…
Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

Psoriatic disease: recent advances in small molecules. #psoriasis #Deucravacitinib For more information blog: drugdiscoveryhub.com/psoriatic-dise…

Psoriatic disease: recent advances in small molecules. #psoriasis #Deucravacitinib
For more information blog: drugdiscoveryhub.com/psoriatic-dise…
まいしん (@chemist58409939) 's Twitter Profile Photo

discovery of LUNA18 as an orally bioavailable cyclic peptide KRAS inhibitor(Chugai Pharmaceutical Co. Ltd.) pubs.acs.org/doi/abs/10.102…

ACS Publications Bio & Med Chem Content (@acsbiomed) 's Twitter Profile Photo

Optimizing the drug-like properties should be your design focus for antibody-drug conjugates (ADC). Research from @AbbVie in #JMedChem Read the article here ➡ go.acs.org/5Bm

Optimizing the drug-like properties should be your design focus for antibody-drug conjugates (ADC). Research from @AbbVie in #JMedChem

Read the article here ➡ go.acs.org/5Bm
Chirosynkem laboratories Pvt Ltd (@chirosynkem) 's Twitter Profile Photo

The first FDA-approved treatment for Demodex Blepharitis, a common eyelid disease caused by microscopic mites living in the eyelashes' hair follicles. #Lotilaner For more information blog: drugdiscoveryhub.com/lotilaner-firs…

The first FDA-approved treatment for Demodex Blepharitis, a common eyelid disease caused by microscopic mites living in the eyelashes' hair follicles. #Lotilaner
For more information blog:
drugdiscoveryhub.com/lotilaner-firs…
Guillaume Laconde (@glaconde34) 's Twitter Profile Photo

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies nature.com/articles/s4141…

Project ESTELLA (@project_estella) 's Twitter Profile Photo

📢Good news from Kemijski inštitut! Our partners have published an article (with Project ESTELLA in the acknowledgements) about lignin and covalent adaptable networks in ACS Sustainable Chemistry & Engineering 📄. 👉Click on the link to read the complete article: pubs.acs.org/doi/10.1021/ac…

Thomä Lab (@labthoma) 's Twitter Profile Photo

Interested in how #molecularglues do the gluing but only have a few minutes to spare? ⏰ Have a look at a one-page digest of our recent manuscript, a new Nature Portfolio format: bit.ly/46bFgLj